Australian Clinical Labs Ltd · ASX:ACL
Australian Clinical Labs — FY2025 Earnings Presentation
22 slides from Australian Clinical Labs's earnings presentation, Aug 26, 2025
Slide 1: ACL FY25 Financial Results ASX Announcement
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au Tuesday, 26 August 2025 ACL FY25 FINANCIAL RESULTS The following announcements to the market are attached: Appendix 4E FY25 financial statem
Slide 2: FY25 Results Presentation
FY25 Results Presentation Melinda McGrath, CEO and Executive Director Matthew Cordingley, CFO 26 August 2025
Slide 3: Contents
FY25 Result – Key Highlights FY25 Result – Financials Contents Growth Strategy & Industry Outlook Outlook & Guidance Appendix
Slide 4: Financial & Operational Highlights
Financial & Operational Highlights Melinda McGrath CEO & Executive Director
Slide 5: FY25 Result – Financial Highlights
FY25 Result – Financial Highlights Strong earnings and Cash Flow growth as operating leverage realised Revenue Strong revenue growth despite challenging market conditions, Revenue ($m) $741.3m with ACL MBS outlays rising 7.8%3, slightly ahead of the broader 369.2 372.1 +6.4% yoy market4 359.1 EBIT1
Slide 6: FY25 Result – Operational Highlights
FY25 Result – Operational Highlights Constant focus on efficiency and profitable revenue growth ACL’s ACL is the only national pathology provider with a single national Laboratory Information System (LIS) Competitive (operating system) which reduces duplication, drives cost efficiencies, and enhance
Slide 7: ESG Highlights
ESG Highlights Delivering strong performance across all areas of our ESG Mission 6
Slide 8: Financials
Financials Matthew Cordingley CFO
Slide 9: FY25 Profit and Loss
FY25 Profit and Loss Sustained growth across all key metrics in FY25 (YoY) and 2H25 (HoH) Actual Actual AUD in millions % Growth 2H FY25 1H FY25 FY25 FY24 Total Revenue 741.3 696.4 6.4% 372.1 369.2 1 Underlying EBITDA 204.0 191.0 6.8% 108.9 95.1 1 Underlying EBIT 68.0 62.6 8.7% 40.7 27.3 1 Underlyin
Slide 10: FY25 Cash Flow
FY25 Cash Flow Strong Cash Flows underpin debt reduction, dividends, and buyback Actual Actual Actual AUD in millions FY25 FY24 2H FY25 1H FY25 Operating CF / Cash EBITDA EBITDA 202.2 181.3 107.5 94.7 120% Non-cash items 3.6 4.1 1.7 1.9 100% 101% 105% Property related payments AASB 16 (136.1) (125.0
Slide 11: FY25 Balance Sheet
FY25 Balance Sheet Balance Sheet deleveraging alongside significant capital returns Actual Actual AUD in millions FY25 FY24 Cash and cash equivalents 21.4 26.1 Highlights Trade and other receivables 72.8 81.4 Inventories and other assets 25.8 26.0 Total current assets 120.1 133.6 Stable cash positio
Slide 12: Growth Strategy & Industry Outlook
Growth Strategy & Industry Outlook Melinda McGrath CEO & Executive Director
Slide 13: Growth Strategy
Growth Strategy Clear opportunity pipeline to drive increased shareholder returns Disciplined Operational Strategic New Strategic Revenue network Improvement & Business Acquisitions Initiatives expansion Restructuring Sustainable and profitable Research program AU pathology acquisitions Digitalisati
Slide 14: Industry Outlook
Industry Outlook Pathology market growth is closing the gap Highlights • The pathology market is closing the gap towards historical trends, notwithstanding H2 pull-back • ~5.8% below historical trend remains an opportunity for revenue growth • Implies a >$35m Revenue opportunity for ACL if the marke
Slide 15: Guidance & Outlook
Guidance & Outlook Melinda McGrath CEO & Executive Director
Slide 16: FY26 Guidance and Outlook
FY26 Guidance and Outlook Revenue of $760m to $780m; Underlying EBIT of $67m to $73m Guidance range for FY26 informed by the following factors and assumptions: - ACL’s continued investment in revenue initiatives and operating efficiencies to partially offset the impact of FY26 government fee cuts Gu
Slide 17: Appendix
Appendix
Slide 18: Partnership with Geneseq
Partnership with Geneseq ACL strategic investment developing genomic test for melanoma ACL/Geneseq partnership Major Milestone Achieved Melaseq is a liquid (plasma) and solid tissue microRNA (genetic) test for Test has achieved very high validation scores. In July 23, Geneseq melanoma that was devel
Slide 19: Reconciliations
Reconciliations Reported & Underlying EBITDA, EBIT and NPAT Statutory Underlying AUD in millions FY25 Insurance Other FY25 Pathology Revenue 717.8 - - 717.8 Clinic/Other Revenue 23.5 - - 23.5 Total Revenue 741.3 - - 741.3 Unusual / Non-Core items EBITDA 202.2 (0.9) 2.8 204.0 EBIT 66.1 (0.9) 2.8 68.0
Slide 20: Reconciliations
Reconciliations AASB 16 to pre-AASB 16 19
Slide 21: Important notice and disclaimer
Important notice and disclaimer Summary information this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these This Presentation contains summary information about Australian Clinical Labs Limited (ACN 645 figures may differ from the figures set out in this
Slide 22: Thank You
Thank You Contact Matthew Cordingley, Chief Financial Officer Matthew.Cordingley@clinicallabs.com.au
Australian Clinical Labs — FY2025 Earnings Presentation on 6ix